Clinical trial · no report yet · Phase 2
PCCTC #: c16-168
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
- NCT03012321 ↗
- Active, not recruiting
- Northwestern University
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 97 | |
| YouTube | 32 | |
| Podcasts | 31 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Prostate Cancer Metastatic Castration-Resistant; Abnormal DNA Repair; Metastatic Prostate Carcinoma; Stage IV Prostate Cancer
- Interventions
- Olaparib; Abiraterone Acetate; Prednisone
- Arms
- Arm I: Abiraterone + Prednisone · Active comparator
- Arm II: Olaparib · Active comparator
- Arm III: Abiraterone + Prednisone + Olaparib · Active comparator
- Olaparib · Active comparator
- Enrollment
- 70 (estimated)
- Primary outcomes
- Objective Progression Free Survival (PFS)
- Sponsor
- Northwestern University with AstraZeneca, National Cancer Institute (NCI)
- Start
- Jan 12, 2017
- Primary completion
- Oct 21, 2023
- Results posted
- No
- Registry record
- NCT03012321 · updated Jun 1, 2026
Publications
linked from the registry- Collins K, Cheng L. Reprint of: morphologic spectrum of treatment-related changes in prostate tissue and prostate cancer: an updated review. Hum Pathol. 2023 Mar;133:92-101. doi: 10.1016/j.humpath.2023.02.007. Epub 2023 Mar 8. PubMed 36898948